Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
GPTRF$0.19-0.01(-5.14%)Grande Portage Resources Ltd. to Attend the 52nd Annual New Orleans Investment Conference[12:14:00 PM ET]ORCL$131.68+5.62(+4.45%)Oracle Reinvents Enterprise Computing for the AI Era with OpenAI Oracle AI World -- Oracle today announced a major new collaboration with OpenAI to redefine how the world's businesses run in the age of AI. By...[12:08:00 PM ET]ORCL$131.68+5.62(+4.45%)Oracle Brings Google TPUs to Oracle Cloud Infrastructure Oracle AI World -- Oracle and Google today announced that Google's Tensor Processing Units (TPUs) will be available through Oracle Cloud...[12:07:00 PM ET]SMP$37.43+0.15(+0.40%)Standard Motor Products, Inc. Announces Third Quarter 2026 Earnings Conference Call Standard Motor Products, Inc. (NYSE: SMP), a leading automotive parts manufacturer and distributor, is scheduled to report its earnings for the three ...[12:06:00 PM ET]SNOW$340.22+5.27(+1.57%)Oracle Expands Native AI and Data Services on OCI with Snowflake Oracle AI World -- Oracle and Snowflake (NYSE: SNOW) today announced that Snowflake AI Data Cloud will be available as a native, first-party service...[12:06:00 PM ET]ORCL$131.68+5.62(+4.45%)Oracle Advances Enterprise Security for the AI Era Oracle AI World -- Oracle today announced Oracle AI Security Mesh, powered by OpenAI. The new offering complements Oracle Cloud Infrastructure (OCI)...[12:05:00 PM ET]ORCL$131.68+5.62(+4.45%)Oracle Introduces Oracle Media Fabric Oracle AI World -- Oracle today announced Oracle Media Fabric, an integrated platform designed to help media companies, streaming providers, and...[12:04:00 PM ET]ORCL$131.68+5.62(+4.45%)Oracle Unveils New Cloud Networking Innovations for AI Oracle AI World -- Oracle today announced new capabilities in Oracle Acceleron, Oracle Cloud Infrastructure's (OCI) suite of networking and...[12:03:00 PM ET]ADT$6.89+0.00(+0.07%)ADT Secures AI Innovation with Oracle Oracle AI World -- ADT Inc. (NYSE: ADT), the trusted leader in smart home security solutions, is expanding its use of AI with Oracle AI...[12:02:00 PM ET]ORCL$131.68+5.62(+4.45%)Oracle Expands Fusion Data Intelligence with New Deep Insight Agents, Operational Analytics, and AI Capabilities Oracle AI World -- Oracle today announced new Oracle Fusion Data Intelligence capabilities that help customers uncover insights closer to the...[12:01:00 PM ET]WDFN$38.500.00(0.00%)Woodlands Financial Services Company Announces Fourth Quarter Cash Dividend[12:00:00 PM ET]CBRS$117.78+9.41(+8.68%)Cerebras and Oracle Team Up to Bring Cerebras AI Inference to Oracle Cloud Infrastructure[12:00:00 PM ET]IVZ$28.95+0.41(+1.45%)Invesco Announces Work with Anthropic to Bring its Custom Portfolio and Practice Management Capabilities to Claude Invesco Ltd. (NYSE: IVZ), a leading global asset management firm, announced today it is working with Anthropic to bring its data to support portfolio ...[12:00:00 PM ET]MSGM$4.47-0.17(-3.56%)Motorsport Games' Proprietary RaceControl Platform Powers Record Concurrent Players for Le Mans Ultimate in Biggest 24 Hours of Le Mans Online Event Yet[12:00:00 PM ET]ORCL$131.68+5.62(+4.45%)Oracle AI Data Platform Brings AI-Assisted Business Context to Enterprise AI Oracle AI World -- Oracle today announced new Oracle AI Data Platform capabilities that help customers build, deploy, and scale enterprise AI by...[12:00:00 PM ET]NVDA$218.72+2.72(+1.26%)NVIDIA and Oracle Expand NVIDIA Vera Rubin to Multi-Gigawatt Scale and Bring NVIDIA Vera CPU to Oracle Cloud Infrastructure[12:00:00 PM ET]

KURA · NASDAQ

Kura Oncology, Inc.

$9.78 +0.18 (+1.87%)

Company overview

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company that develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-lysine K-specific methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia, and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$870M
Employees
192
Headquarters
San Diego, CA
Website
kuraoncology.com
CEO
Troy Edward Wilson
Listed
September 16, 2015
P/E
-2.92
Dividend yield
0.00%

Company financials

Revenue
$71.6M
Gross profit
$67.8M
Operating income
-$318M
EBITDA
-$298M
Net income
-$295M
EPS
-$3.35
Total assets
$653M
Total debt
$24.3M
Gross margin
94.66%
Net margin
-411.19%
Earnings yield
-34.29%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

No geographic segmentation.

Showing FY 2025

Price chart

8.179.6611.1512.6314.12
KURA 1D NASDAQ O9.70H9.84L9.56C9.60-0.01 (-0.16%)Vol170.34K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
KURAKura Oncology, Inc. Stock news Will Kura Oncology (KURA) Report Negative Q3 Earnings? What You Should Know Zacks Investment Research
KURAKura Oncology, Inc. Stock news Kura Oncology Launches $50M-Backed Diabetes Venture for Oral Menin Inhibitor MarketBeat
KURAKura Oncology, Inc. Stock news Kura Oncology, Inc. (KURA) Discusses KO-7246 Data and Development Strategy for Menin Inhibitors in Diabetes Transcript Seeking Alpha
KURAKura Oncology, Inc. Press release Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in Diabetes GlobeNewswire
KURAKura Oncology, Inc. Press release Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian's Launch and KO-7246 Preclinical Data in Diabetes GlobeNewsWire
KURAKura Oncology, Inc. Press release Kura Oncology Reports Inducement Grants Under Nasdaq GlobeNewswire
KURAKura Oncology, Inc. Stock news This Toll Brothers Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday Benzinga
KURAKura Oncology, Inc. Press release Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes GlobeNewswire
KURAKura Oncology, Inc. Stock news Squarepoint Ops LLC Sells 78,432 Shares of Kura Oncology, Inc. $KURA Defense World
KURAKura Oncology, Inc. Stock news Kura Oncology, Inc. (KURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Seeking Alpha
KURAKura Oncology, Inc. Press release Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes GlobeNewsWire
KURAKura Oncology, Inc. Press release Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer GlobeNewswire
KURAKura Oncology, Inc. Press release Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
KURAKura Oncology, Inc. Stock news KURA Stock Gains 37.6% in a Month: Here's What You Need to Know Zacks Investment Research
KURAKura Oncology, Inc. Press release Kura Oncology to Participate in Three Investor Conferences in September GlobeNewsWire
KURAKura Oncology, Inc. Stock news Kura Oncology (KURA) Upgraded to Buy: What Does It Mean for the Stock? Zacks Investment Research
KURAKura Oncology, Inc. Stock news Kura Oncology: 'Strong Buy': Ziftomenib AML Expansions With Different Regimens Could Boost KOMZIFTI's Prospects Seeking Alpha
KURAKura Oncology, Inc. Stock news Kura Oncology CEO Buys 100,000 Shares for $1.2 Million. Does This Large Buy Bode Well for Shares in 2026? The Motley Fool
KURAKura Oncology, Inc. Stock news Kura Oncology (KURA) is a Great Momentum Stock: Should You Buy? Zacks Investment Research
KURAKura Oncology, Inc. Stock news Does Kura Oncology (KURA) Have the Potential to Rally 178.55% as Wall Street Analysts Expect? Zacks Investment Research
See more
FAQ

Questions about Kura Oncology, Inc.

What does Kura Oncology, Inc. do?
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company that develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-lysine K-specific methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia, and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications.
What is KURA's market cap?
Kura Oncology, Inc. (KURA) is a listed stock with a live quote. The latest market cap on this page is $870M.
Where is Kura Oncology, Inc. headquartered?
Kura Oncology, Inc. is headquartered in San Diego, CA.
How do I get KURA news from the API?
Call GET /v1/news?tickers=KURA. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does KURA news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for KURA, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the KURA price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs